DOR/ISL

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ImmunodeficiencyHIV-1

46 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

1

Fuzeon

CConrado Roberto Hoffmann Filho

Approved

72

Adenocard

Astellas

Approved

—3

Rayos

RRoxane Laboratories

Approved

14

Busulfex

Akero Therapeutics

Approved

15

Viramune

Boehringer Ingelheim

Approved

16

Cabenuva

GSK

Phase 3

47

Immunoglobulin

Sanofi

Phase 3

28

Cytosar

Teva

Phase 2

19

Bicnu

MMelissa K Accordino

Phase 2

110

Vepesid

AAvyxa

Phase 2

1Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunodeficiency7 trials

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

Active, not recruiting·Merck & Co.·Phase 3·NCT05766501·641 enrolled

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

Completed·Merck & Co.·Phase 3·NCT04223791·643 enrolled

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

Completed·Merck & Co.·Phase 3·NCT04233879·599 enrolled

Show 4 more trials

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

Active, not recruiting·Merck & Co.·Phase 3·NCT05630755·514 enrolled

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

Completed·Merck & Co.·Phase 2·NCT04295772·42 enrolled

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

Completed·Merck & Co.·Phase 3·NCT04233216·35 enrolled

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

Active, not recruiting·Merck & Co.·Phase 3·NCT05631093·553 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

Completed·Merck & Co.·Phase 3·NCT04223778·672 enrolled

Female1 trial

A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)

Completed·Merck & Co.·Phase 1·NCT07086079·12 enrolled

HIV-11 trial

A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Doravirine/Islatravir (100 mg/0.25 mg) in Pediatric Participants With HIV-1 Infection Who Are Virologically Suppressed or Treatment-Naïve, Are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg

Not yet recruiting·Merck & Co.·Phase 2·NCT07862569·45 enrolled

HIV-1 infection1 trial

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants

Active, not recruiting·Merck & Co.·Phase 3·NCT05705349·537 enrolled

Details

Drug Info

Related News